{"prompt": "['Alliance A171601', '2.3.4 To explore the association between baseline chronic inflammatory mediator levels and', 'decline in physical function as assessed by the cancer-specific geriatric assessment.', '2.3.5 To explore the correlation between inherited single nucleotide polymorphisms (SNPs) in', 'cell cycle pathway genes and in genes that metabolize palbociclit and treatment efficacy', 'and toxicity (clinical outcomes) in elderly patients undergoing combined endocrine therapy', 'plus palbociclib for estrogen receptor positive, HER2 negative metastatic breast cancer.', '2.3.6 To explore whether genes in CYP19A, CYP2A6 and ESRI will also correlate with treatment', 'efficacy and toxicity (clinical outcomes) in elderly patients undergoing combined endocrine', 'therapy plus palbociclib for estrogen receptor positive, HER2 negative metastatic breast', 'cancer.', '2.3.7 To refine a population pharmacokine model using NONMEM for palbociclit based on', 'that of Sun and Wang (ESMO Poster Presentation 462P 2014) taking account of relevant', 'intrinsic and extrinsic factors.', '2.3.8 To determine the intrapatient and interpatient variability of palbociclib exposure (AUC) in', 'older breast cancer patients receiving palbociclib plus letrozole/fulvestrant.', '2.3.9 To explore the exposure (AUC/Cmux) toxicity (neutropenia, thrombocytopenia) relationship', 'for palbociclib when combined with letrozole/fulvestrant in older breast cancer patients.', '14', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '3.0', 'PATIENT SELECTION', 'For questions regarding eligibility criteria, see the Study Resources page. Please note that the', 'Study Chair cannot grant waivers to eligibility requirements.', '3.1', 'On-Study Guidelines', 'This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled.', 'All relevant medical and other considerations should be taken into account when deciding', 'whether this protocol is appropriate for a particular patient. Physicians should consider the risks', 'and benefits of any therapy, and therefore only enroll patients for whom this treatment is', 'appropriate.', 'Physicians should consider whether any of the following may render the patient inappropriate', 'for this protocol:', 'Psychiatric illness which would prevent the patient from giving informed consent.', 'Medical condition such as uncontrolled infection (including HIV), uncontrolled', 'diabetes mellitus or cardiac disease which, in the opinion of the treating physician,', 'would make this protocol unreasonably hazardous for the patient.', 'Concomitant medications:', 'Chronic concomitant treatment with strong inhibitors of CYP3A is strongly discouraged', 'on this study. Patients on strong CYP3A inhibitors must discontinue the drug prior to', 'registration on the study. See section 8.1.10 for more information.', 'Chronic concomitant treatment with strong CYP3A inducers is strongly discouraged', 'Patients must discontinue the drug prior to the start of study treatment. See section', '8.1.11 for more information.', 'Chronic concomitant treatment with CYP2A6 substrates is strongly discouraged for', 'patients who are being treated with letrozole. Patients must discontinue the drug prior', 'to the start of study treatment. See section 8.1.12 for more information.', 'Life expectancy of less than 6 months', '15', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '3.2', 'Eligibility Criteria', \"Use the spaces provided to confirm a patient's eligibility by indicating Yes or No as appropriate.\", 'It is not required to complete or submit the following page(s).', 'When calculating days of tests and measurements, the day a test or measurement is done is', 'considered Day 0. Therefore, if a test were done on a Monday, the Monday one weeklater would', 'be considered Day 7.', '3.2.1', 'Documentation of Disease: Estrogen receptor positive and/or progesterone', 'receptor (PR) positive, HER2 negative metastatic breast cancer. Histologic', 'confirmation is required.', '3.2.2', 'Measurable disease or non-measurable disease (see Section 11.3)', '3.2.3', 'Planning to begin palbociclib for metastatic disease. One prior line of', 'endocrine therapy and/or chemotherapy for metastatic disease is allowed.', 'Patients may begin or have already begun endocrine therapy before they start palbociclib', 'treatment, but no more than two weeks prior to registration.', '3.2.4', 'No prior therapy with a CDK inhibitor.', '3.2.5', 'Resolution of all acute toxic effects of prior therapy or surgical procedures to', 'CTCAE Grade 1 (except alopecia) or to baseline toxicities prior to previous therapy', 'or surgical procedures, prior to registration.', '3.2.6', 'No untreated brain metastases. Patients with treated brain metastases must have', 'completed treatment with steroids to be eligible.', '3.2.7', 'No known interstitial lung disease.', '3.2.8. No second malignancies other than non-melanoma skin cancers or cervical', 'carcinoma in situ. However, patients are not considered to have a \"currently active\"', 'malignancy if they have completed therapy and are free of disease for > 3 years.', '3.2.9', 'No active infection requiring treatment with antibiotics.', '3.2.10', 'Patients must be able to swallow and retain oral medication.', '3.2.11', 'Patient Age: > 70 years', '3.2.12', 'ECOG Performance Status 0, 1 or 2.', '3.2.13', 'Patients must be able to read and comprehend English or Spanish.', '3.2.14', 'Required Initial Laboratory Values:', 'Absolute neutrophil count > 1500/mm\u00b3 (1.5 X 109/L)', '(ANC)', 'Platelet count: > 100,000/mm\u00b3 (100x 109/L)', 'Creatinine clearance:', '30 ml/min*', 'Total serum bilirubin', \"VI 1.5 ULN (<3 ULN if Gilbert's disease)\", 'AST and/or ALT VI 3 X ULN ( 5.0 X ULN if liver metastases', 'present)', 'Alkaline phosphatase < 2.5 X ULN (< 5 X ULN if bone or liver', 'metastases present)', '* Calculated using the Cockcroft-Gault formula', '16', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}